The deal activity in the global healthcare sector, including pharmaceuticals and medical equipment, has witnessed second consecutive week of growth, according to GlobalData’s deals database.
The number of deals increased by 5.9% during the week ended 5 April 2020, compared to the earlier week.
GlobalData analyst Aurojyoti Bose said: “This marks the second consecutive week of growth in deal activity for the healthcare sector. Amid COVID-19 concerns, the healthcare sector has been showcasing resilience and witnessing growth in deal activity.”
The US saw a decline in deal activity, while China witnessed growth during the week ended 5 April.
Bose continued: “Announcement of venture financing, partnership and merger and acquisitions (M&A) deals increased by 45.8%, 8.6% and 54.5%, respectively, while licensing agreement and private equity deal volume remained at the same level during the week ended 5 April 2020 compared to the previous week. On the other hand, equity offerings deal volume dropped by 32.5%.”
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.